tiprankstipranks
Trending News
More News >
Sutro Biopharma Inc (STRO)
NASDAQ:STRO
Advertisement

Sutro Biopharma (STRO) AI Stock Analysis

Compare
688 Followers

Top Page

ST

Sutro Biopharma

(NASDAQ:STRO)

Rating:39Underperform
Price Target:
$0.50
▼(-34.21%Downside)
Sutro Biopharma's overall score is primarily impacted by its precarious financial position and bearish technical indicators. The NASDAQ non-compliance notice further exacerbates the risks, creating an unattractive investment profile at this time.
Positive Factors
Financial Stability
Despite the challenges, Sutro maintains a solid cash position of $316.9 million, which suggests financial stability.
Scientific Innovation
Sutro's cell-free platform and linker chemistry allow the development of ADCs with a higher drug-to-antibody ratio, enabling higher dosing levels and improved efficacy.
Strategic Partnerships
Sutro Biopharma partnered ROR1 ADC STRO-003 with Ipsen and is developing two immunostimulatory ADCs with Astellas, which could bring in over $1.6 billion in milestones plus royalties.
Negative Factors
Clinical Risk
There is a risk that Sutro Biopharma's drugs may fail in the clinic, and the company will likely require additional capital.
Program Discontinuation
The impact of luvelta’s discontinuation continues to weigh on investor sentiment, although management has moved swiftly to reposition the story around a next-generation ADC pipeline.
Workforce Reduction
Sutro announced a near-50% reduction in headcount, indicating significant restructuring within the company.

Sutro Biopharma (STRO) vs. SPDR S&P 500 ETF (SPY)

Sutro Biopharma Business Overview & Revenue Model

Company DescriptionSutro Biopharma, Inc. (STRO) is a biotechnology company focused on developing and manufacturing next-generation oncology therapeutics. The company specializes in the development of antibody-drug conjugates (ADCs), bispecific antibodies, and other protein therapeutics for cancer treatment. Sutro leverages its proprietary cell-free protein synthesis platform, XpressCF+, to create complex biologics that can target cancer cells more precisely, offering potentially improved therapies for patients.
How the Company Makes MoneySutro Biopharma generates revenue through a combination of product sales, collaboration agreements, and licensing. The company's proprietary XpressCF+ platform is a key driver of collaborations with other pharmaceutical companies, where Sutro receives upfront payments, research funding, milestone payments, and potentially royalties on commercialized products. Additionally, Sutro may earn revenue from the direct commercialization of its own pipeline of oncology therapeutics, though this depends on successful development and regulatory approval of these drugs. Partnerships with larger biotech firms for co-development and co-commercialization are significant contributors to its earnings, allowing Sutro to leverage additional resources and expertise in the development of its therapeutic candidates.

Sutro Biopharma Financial Statement Overview

Summary
Sutro Biopharma faces significant financial challenges, including negative equity, declining revenues, and negative cash flows. These factors indicate high financial risk typical of early-stage biotech firms but remain concerning.
Income Statement
32
Negative
Sutro Biopharma shows a volatile revenue trend with a recent revenue decline in the TTM period. The gross profit margin has dramatically decreased, indicating rising costs or reduced pricing power. Net profit margins remain negative, reflecting ongoing losses, although these are consistent with typical biotech firms in early stages. The EBIT and EBITDA margins are also negative, highlighting operational challenges.
Balance Sheet
25
Negative
The balance sheet exhibits a negative stockholder equity in the TTM period, indicating potential financial instability. The debt-to-equity ratio is irrelevant due to negative equity, but the total liabilities exceed total assets, raising concerns about solvency. Overall, the financial leverage is high, and equity financing may be necessary to maintain operations.
Cash Flow
28
Negative
Sutro Biopharma's cash flow statement reveals a negative operating cash flow, suggesting operational inefficiencies or high R&D costs typical in biotech. The free cash flow is negative, and there's a significant reliance on financing activities, raising sustainability concerns if external funding diminishes.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue62.04M153.73M67.77M61.88M42.72M
Gross Profit54.83M146.91M59.48M52.11M-34.24M
EBITDA-180.45M-67.92M-105.07M-98.52M-23.75M
Net Income-227.46M-106.79M-119.20M-108.67M-36.20M
Balance Sheet
Total Assets387.21M470.74M406.94M341.41M394.11M
Cash, Cash Equivalents and Short-Term Investments316.89M375.62M302.34M197.94M368.14M
Total Debt23.15M33.63M67.52M57.37M24.55M
Total Liabilities342.61M321.09M189.90M88.84M62.06M
Stockholders Equity44.60M149.65M217.05M252.56M332.05M
Cash Flow
Free Cash Flow-194.64M-115.93M-4.31M-97.00M-74.93M
Operating Cash Flow-191.54M-111.62M3.55M-81.68M-67.80M
Investing Cash Flow218.51M-3.92M-35.02M-97.31M604.00K
Financing Cash Flow94.05M137.55M48.31M3.26M269.25M

Sutro Biopharma Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.76
Price Trends
50DMA
0.83
Negative
100DMA
0.89
Negative
200DMA
1.77
Negative
Market Momentum
MACD
-0.02
Negative
RSI
45.89
Neutral
STOCH
27.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STRO, the sentiment is Negative. The current price of 0.76 is below the 20-day moving average (MA) of 0.77, below the 50-day MA of 0.83, and below the 200-day MA of 1.77, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 45.89 is Neutral, neither overbought nor oversold. The STOCH value of 27.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STRO.

Sutro Biopharma Risk Analysis

Sutro Biopharma disclosed 76 risk factors in its most recent earnings report. Sutro Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Sutro Biopharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.35B-0.07-63.71%2.81%16.17%0.03%
CUCUE
51
Neutral
$67.81M-221.66%13.83%37.66%
ININO
44
Neutral
$70.83M-132.44%-60.52%42.41%
39
Underperform
$65.39M-83.71%
39
Underperform
$64.19M-679.15%-56.88%-57.57%
38
Underperform
$20.70M-1949.77%-89.76%80.28%
28
Underperform
$56.56M-2355.27%-100.00%52.65%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
STRO
Sutro Biopharma
0.76
-3.23
-80.95%
CYCC
Cyclacel Pharmaceuticals
13.07
-382.93
-96.70%
INO
Inovio Pharmaceuticals
1.39
-9.17
-86.84%
CUE
Cue Biopharma
0.90
0.13
16.88%
APLT
Applied Therapeutics
0.46
-4.63
-90.96%
UNCY
Unicycive Therapeutics
4.43
0.37
9.11%

Sutro Biopharma Corporate Events

Delistings and Listing ChangesStock SplitRegulatory Filings and Compliance
Sutro Biopharma Faces NASDAQ Non-Compliance Notice
Negative
Jun 25, 2025

On June 20, 2025, Sutro Biopharma received a notice from NASDAQ indicating non-compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Global Market. The company has until December 17, 2025, to meet this requirement, with options for an additional compliance period if necessary. Failure to comply could result in delisting, but the company plans to monitor its stock price and may implement a reverse stock split to regain compliance.

The most recent analyst rating on (STRO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Sutro Biopharma stock, see the STRO Stock Forecast page.

Executive/Board ChangesShareholder MeetingsStock Split
Sutro Biopharma Adopts Key Proposals at Annual Meeting
Neutral
Jun 10, 2025

On June 6, 2025, Sutro Biopharma held its 2025 Annual Meeting of Stockholders, where several key proposals were adopted. These included the election of three Class I directors to serve until 2028, the ratification of Ernst & Young LLP as the independent accounting firm for 2025, approval of executive compensation on a non-binding basis, and an amendment to the company’s Restated Certificate of Incorporation to potentially enact a reverse stock split.

The most recent analyst rating on (STRO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Sutro Biopharma stock, see the STRO Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 12, 2025